Active factor (INN – International Non-proprietary Name)

Cefotaximum (as sodium salt)


Code ATC: J01DA10


Pharmacotherapeutic group

Antibiotics (group of cephalosporin)


Pharmacological properties

Cephalosporin antibiotics of IIIrd generation. Possesses high tropaic to penicillin connecting albumin of microbes’ membranes, blocks polymerase of peptidoglycane, destroys biosynthesis of mucopeptide of cell wall of microorganisms.
Possesses broad-spectrum antimicrobial action. It is active re Staphylococcus aureus including those  producing  penicillinase,  Staphylococcus epidermidis, some stock cultures Enterococcus spp., Streptococcus pneumoniae  (especially Diplococcus pneumoniae), Streptococcus pyogenes (beta- hemolytic streptococcus of group A), Streptococcus agalactiae  (streptococcus of group B), Bacillus subtilis, Bacillus mycoides, Corynebacterrium Diphtheriae, Erysipelothrix insidiosa, Eubacterium, Enterobacter aerogenes, Enterobacter cloacae, Escherichia coli, Acinetobacter spp., Haemophilus influenzae, including ampicillin resisting stock cultures, Haemophilus parainfluenzae, Klebsiella oxytoca,  Klebsiella pneumoniae, Morganella morganii, Neisseria meningitides, Neisseria gonorrhoeae, including stock cultures, producing penicillinase, Propionibacterium, Proteus mirabilis, Proteus vulgaris, Proteus inconstans, Serratia marcescens, many stock cultures Pseudomonas aeruginosa, Citrobacter spp., Salmonella spp., Providencia rettgeri, Shigella spp., Serratia spp., Viellonella, Yersinia, Bordetella pertussis, Moraxella, Aeromonas hydrophilia, Eusobacterium, Bacteroides spp., Clostridium species, Peptostreptococcus species, Peptococcus spp. It may influence to multi resistant stock cultures resisting to penicillin, cephalosporin of 1st generations and aminoglycoside. As for gram-positive coccus is less active, than cephalosporin of 1st and 2nd generation.
Resisting cefotaxime: Acinetobacter baumanii, Bacteroides fragilis; Clostridium difficile; Enterococcus spp.; Gram negative anaerobes; Listeria monocytogenes, Methi-R staphylococcus;
Pseudonas aeruginosa, cepacia; Stenotrophomonas maltophilia.               
Carcinogenicity, mutagenicity, effect to fecundity.

Continuous researches at animals for estimation of  carcinogenicity did not carry out. Mutagenic effect does not revealed (micronucleus test on mousse, Ames test). Effect to  fecundity at rats does not revealed at intramuscular injection (i.m) in doses 250 mg/kg/day (0,2 MRDCh, in mg/m2) and at mousse at intravenous  injection (i.v) in doses 2000 mg/kg/day (0,7 MRDCh, in mg/m2).   


Indications for use

Serious bacterial infections caused by sensitive microorganisms: infections of respiratory tract and organs of EENT (except enterococcus), skin and soft tissues (including infected maim and ambustions), bones and joints, urinary tracts, organs of small pelvis, obstetric-gynecologic (including clamidiosis, gonorrhea, including caused by microorganisms egesting penicillinase), bacillemia, hematosepsis, peritonitis, intra-abdominal infections, bacterial meningitis (except for listeric meningitis), endocarditis, Lyme disease, typhoid fever, infections against immunodeficient; infection prevention after surgery operations including at gastrointestinal tract.


Pharmaceutical form

Powder for preparation of an injection solution in flasks by 0,5 g and 1,0 g or in a set with solvent (“water for injections” in ampoules by 0,5 ml).



Local anaesthetic drugs
Nootropic drugs
Antihypertensive drugs
Drugs for a parenteral food
Medicines applied at poisonings and intoxications
Medicines for metabolic processes correction
Medicines for peripheric blood circulation
Mineral drugs, microcells
Salt solutions
Analgesic and antispasmodic drugs
Nonsteroidal anti-inflammatory drugs